Omnipod® 5 Automated Insulin Delivery System
Omnipod 5 is the first wearable, tubeless, hybrid closed loop system that integrates with Dexcom G6 and G7 Sensors, for people with type 1 diabetes aged 2 years and older.
The Omnipod 5 System works with the Dexcom G6 and G7 Sensors to continuously adjust, correct, and automatically deliver basal insulin according to your patients’ needs.
3 Simple Parts
Controller + Pod + Sensor


Omnipod 5 Controller
Take control of the system with the Omnipod 5 Controller. Monitor and control the Pod using Bluetooth® wireless technology.


Pod
Tubeless, wearable, and waterproof*, the Pod, with built-in SmartAdjust™ technology, sits right on your patient’s body and automatically adjusts insulin delivery for up to 3 days or 72 hours.


Sensor
Continuously sends glucose values to the Pod, so your patients can get real-time data† without the routine fingerpricks‡.


SmartAdjust™ Technology

Predicts
Glucose 60 minutes into the future

Adjusts
Insulin delivery using the selected glucose target

Delivers
Insulin doses every 5 minutes (as needed)
SmartAdjust™ technology is at the heart of Omnipod 5, proactively managing insulin delivery every 5 minutes. It automatically increases, decreases or pauses insulin delivery to your patient’s personal needs which may help to prevent against highs and lows.1
Time in range
76% of time in range for adults and adolescents (target 6.1 mmol/L) 68% of total time in range for children (2-13.9 years)1,2
HbA1c
Significantly reduced by 0.5% in very young children (2.0-5.9 years), 0.7% in children (6-13.9 years) and 0.4% in adults and adolescents (14-70 years)1,2
Hyperglycemia
Time spent in hyperglycemia in children and 24% in adults and adolescents1
Hypoglycemia
60% reduction in time in hypoglycemia overnight and 46% overall in adults and adolescents1
Safety: There were 3 severe hypoglycaemia and 1 DKA events during the pivotal study. These events were not related to automated insulin delivery malfunction.1
Omnipod 5 improved users’ quality of life in clinical studies3,4
- Parents of children using Omnipod 5 reported improvements in quality of life, sleep quality, confidence avoiding hypoglycemia, and mental well-being
- Adults using Omnipod reported improvements in diabetes distress, stress eating, confidence avoiding hypoglycemia, and mental well-being
†Compatible with the Dexcom G6 and Dexcom G7 Sensors. Sensor is required for Automated Mode. Boluses for meals and corrections are still necessary. Sensors are sold separately and require a separate prescription. The Dexcom Sensors must be used with the respective Dexcom mobile app. The Dexcom receiver is not compatible. Devices compatible with Dexcom apps can be found at https://www.dexcom.com/compatibility.
‡Routine fingerpricks required for diabetes treatment decisions if symptoms or expectations do not match readings.
1. Brown SA, et al. Diabetes Care. 2021;44(7):1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6-70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, p<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, p<0.0001. Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs 6.78% or 55 mmol/mol vs. 51 mmol/mol, p<0.0001; 7.67% vs 6.99% or 60mmol/mol vs 53 mmol/mol), p<0.0001. Mean time >10.0 mmol/L or >180mg/dL (12AM-<6AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 32.1% vs. 20.7%; 42.2% vs 20.7%, p<0.0001, respectively. Mean time >10.0 mmol/L or >180mg/dL (6AM-<12AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 32.6% vs. 26.1%; 46.4% vs 33.4%, p<0.0001, respectively. Mean time <3.9 mmol/L or <70 mg/dL (12AM-<6AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 3.64% vs. 1.17%, p<0.0001; 2.51% vs. 1.78, p=0.0456, respectively. Mean time <3.9 mmol/L or <70 mg/dL (6AM-<12AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 2.64% vs. 1.37%, p<0.0001; 2.13% vs. 1.98%, p=0.2545, respectively. Mean time >180 mg/dL or >10 mmol/L overall in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, p<0.0001, respectively. Mean time <70 mg/dL or <3.9 mmol/L in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.9% vs. 1.3%, p<0.0001; 2.2% vs. 1.8%, p=0.8153, respectively. Results measured by CGM.
2. Sherr JL, et al. Diabetes Care. 2022;45(8):1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system. Mean HbA1c as measured in very young children, ST vs. Omnipod 5 use:7.4% vs 6.9% or 57 mmol/ml vs. 53 mmol/mol; (p<0.0001). Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, p<0.0001. Mean time >10.0 mmol/L or >180mg/dL (12AM-<6AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 38.4% vs. 16.9%, p<0.0001, respectively. Mean time >10.0 mmol/L or >180mg/dL (6AM-<12AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.7% vs. 33.7%, P<0.0001, respectively. Mean time <3.9 mmol/L or <70 mg/dL (12AM-<6AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.41% vs. 2.13%, p=0.0185. Mean time <3.9 mmol/L or <70 mg/dL (6AM-<12AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.44% vs. 2.57%, p=0.0799.
3. Hood KK et al. Diabetes Obes Metab. 2024. Study of 81 children aged 6-11.9 with type 1 diabetes using standard therapy (ST) for 2 weeks followed by 3-months of the Omnipod 5 System. Mean caregiver self-reported Hypoglycemia Confidence Scale score ST vs Omnipod 5: 3.34 vs 3.59, p-value <0.0001, respectively. During the Omnipod 5 pivotal trial, parents of children aged 6-11.9 years (N=82) experienced an improvement in emotional distress levels and mental well-being survey scores after 3 months of Omnipod 5 use compared to standard therapy: mean P-PAID-C score = 40.7 vs. 47.4; mean WHO-5 score = 72.9 vs. 67.5, respectively. During the Omnipod 5 pivotal trial, adults aged 18-70 (N=115) experienced an improved diabetes distress survey score after 3 months of AID use: mean: 1.48 vs. 1.64 (p< 0.001). During the Omnipod 5 pivotal trial, parents of children aged 6-11.9 years (N=82) experienced an improvement in emotional distress levels and mental well-being survey scores after 3 months of Omnipod 5 use compared to standard therapy: mean P-PAID-C score = 40.7 vs. 47.4; mean WHO-5 score = 72.9 vs. 67.5, respectively. During the Omnipod 5 pivotal trial, parents of children 6-11.9 years (N=82) experienced an improvement in sleep quality survey score after 3 months of Omnipod 5 use compared to standard therapy: mean PSQI Overall Sleep Quality Subscore = 0.70 vs 1.12, respectively.
4. Polonsky WH et al. Diabetes Res Clin Pract 2022;190:109998. Study of 115 adults aged 18-70 years with type 1 diabetes using standard therapy (ST) for 2 weeks followed by 3-months of the Omnipod 5 System. Mean self-reported Hypoglycemia Confidence Scale score ST vs Omnipod 5: 3.52 vs 3.65, p-value = 0.0002, respectively. Adults aged 18-70 (N=115) experienced reduction in eating distress score in T1-DDS survey after 3 months of Omnipod 5 use vs baseline: 1.73 vs. 1.97, (p=0.0003), respectively.